Safety of bevacizumab (BV) combined with chemotherapy (CTX) in patients (pts) with non-small cell lung cancer (NSCLC): interim results from the ARIES Lung observational cohort study (OCS)

被引：0

作者：

Jahanzeb, M. ^{[1
]}

Fischbach, N. ^{[2
]}

Kosty, M. ^{[3
]}

Kumar, P. ^{[4
]}

Spigel, D. ^{[5
]}

Wozniak, A. ^{[6
]}

Teng, S. L. ^{[7
]}

Wang, L. ^{[8
]}

Sing, A. ^{[9
]}

Lynch, T. ^{[10
]}

机构：

[1] Lynn Reg Canc Ctr, Hematol Oncol Dept Internal Med, Boca Raton, FL USA

[2] Oncol Associates Bridgeport PC, Hematol Oncol, Fairfield, CT USA

[3] Scripps Clin, La Jolla, CA 92037 USA

[4] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Karmanos Canc Inst, Detroit, MI USA

[7] Genentech Inc, Biostat, San Francisco, CA 94080 USA

[8] Genentech Inc, Epidemiol, San Francisco, CA 94080 USA

[9] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA

[10] Yale Canc Ctr, New Haven, CT USA

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71719-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：507 / 507

页数：1